RECEIVED CENTRAL FAX CENTER

JUL 1 2 2006

Approved for use through 07/31/2006, QMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, n	no persons are required to respond to a coll Application Number	oction of information L	nless it di	solavs a valid OMB control number.
	Filing Date			
TRANSMITTAL	First Named Inventor	January 20, 2006		
FORM	Art Unit	MUNT, Freser et al.		
	Examiner Name	Not Known		
(to be used for all correspondence after initial fill	ling)	Not Known		
Total Number of Pages in This Submission 2	Attorney Docket Number	101149-1P US		
	ENCLOSURES (Check all	mar apply)	After Al	lowance Communication to TC
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority	Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence of Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on Cl	Abst	Appeal (Appeal Propriet Status in Other Education):	Enclosure(s) (please Identify
Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53	TURE OF APPLICANT, ATTO	RNEY, OR AG	ENT	
Firm Name AstraZeneca Pharmaceuticals (address associated with Customer No. 22466)				
Signature & Little				
Printed name Kenneth F. Mitchell				
Date July	12 2006	Reg. No. 42,00	7.	
CERTIFICATE OF TRANSMISSION/MAILING				
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mall in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:				
Signature Marie Greloch				
Typed or printed name Marie M. Greloch			Date	7-12-06

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTQ-9199 and select option 2.

Application No. 10/565,464

ABSTRACT

5 Piperidine compounds according to Formula I

$$\begin{array}{c|c}
N & (CH_2)_m - X - (CH_2)_n & (CH_2)_q \\
N & (CH_2)_p & N & Z & Ar
\end{array}$$
(I)

wherein R¹, m, X, n, p, q, Y, Z and Ar are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy and in the preparation of medicaments.